Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of SHR-1139 injection in moderate to severe active ulcerative colitis
CTR20254171Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2025
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1139 in autoimmune colitis, sponsored by Hengrui Therapeutics. Started Dec 2025; status: active.
02
Drugs
SHR-1139
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20254171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254171.